Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Open in Screener

NKTR

Nektar Therapeutics

Jun 17 • 01:50PM ET

1.18

Dollar change +0.01
Percentage change 0.85	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF SCHA VHT PRFZ SCHB NANC AVUS

Index	-	P/E	-	EPS (ttm)	-0.92	Insider Own	2.89%	Shs Outstand	191.38M	Perf Week	-2.07%
Market Cap	217.14M	Forward P/E	-	EPS next Y	-0.69	Insider Trans	-2.61%	Shs Float	178.71M	Perf Month	-34.44%
Income	-175.84M	PEG	-	EPS next Q	-0.20	Inst Own	59.55%	Short Float	1.53%	Perf Quarter	38.82%
Sales	90.17M	P/S	2.41	EPS this Y	44.14%	Inst Trans	-4.28%	Short Ratio	1.25	Perf Half Y	124.76%
Book/sh	0.69	P/B	1.71	EPS next Y	14.32%	ROA	-36.72%	Short Interest	2.74M	Perf Year	109.07%
Cash/sh	1.57	P/C	0.75	EPS next 5Y	-7.30%	ROE	-95.68%	52W Range	0.41 - 1.93	Perf YTD	108.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-51.83%	52W High	-38.80%	Beta	0.66
Dividend TTM	-	Quick Ratio	5.79	Sales past 5Y	-20.42%	Gross Margin	60.91%	52W Low	185.99%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	6.10	EPS Y/Y TTM	58.37%	Oper. Margin	-147.13%	RSI (14)	36.79	Volatility	8.29% 9.23%
Employees	137	Debt/Eq	1.83	Sales Y/Y TTM	1.51%	Profit Margin	-195.02%	Recom	3.50	Target Price	1.60
Option/Short	Yes / Yes	LT Debt/Eq	1.68	EPS Q/Q	73.95%	Payout	-	Rel Volume	0.55	Prev Close	1.17
Sales Surprise	41.05%	EPS Surprise	0.00%	Sales Q/Q	0.21%	Earnings	May 09 AMC	Avg Volume	2.19M	Price	1.18
SMA20	-17.83%	SMA50	-20.29%	SMA200	41.75%	Trades		Volume	818,000	Change	0.85%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Resumed	JP Morgan	Underweight
Nov-09-23	Upgrade	TD Cowen	Market Perform → Outperform
May-10-23	Upgrade	Jefferies	Underperform → Hold	$1.50 → $1
Feb-24-23	Downgrade	Jefferies	Hold → Underperform	$3.20 → $1.50
Aug-08-22	Downgrade	JP Morgan	Neutral → Underweight
May-31-22	Resumed	Jefferies	Hold	$12 → $4
Apr-18-22	Downgrade	Goldman	Neutral → Sell	$3
Mar-15-22	Downgrade	Mizuho	Buy → Neutral	$35 → $8
Mar-15-22	Downgrade	Cowen	Outperform → Market Perform
Mar-14-22	Downgrade	William Blair	Outperform → Mkt Perform
Mar-14-22	Downgrade	Stifel	Buy → Hold	$24 → $5
Mar-14-22	Downgrade	BTIG Research	Buy → Neutral
Mar-14-22	Downgrade	BofA Securities	Neutral → Underperform	$18 → $6
Mar-09-22	Upgrade	Oppenheimer	Perform → Outperform	$21
Nov-08-21	Upgrade	The Benchmark Company	Hold → Buy	$20
Sep-10-21	Initiated	BofA Securities	Neutral	$18
Jun-28-21	Upgrade	Stifel	Hold → Buy	$22 → $24
May-18-21	Resumed	Goldman	Neutral	$24
Feb-22-21	Downgrade	The Benchmark Company	Buy → Hold
Jan-06-21	Initiated	Stifel	Hold	$18

Show Previous Ratings

Jun-12-24 09:30AM	Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024 (PR Newswire)
May-30-24 06:00PM	Nektar Management to Present at Upcoming Investor Conferences (PR Newswire) -8.70%
May-10-24 04:41PM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript (Insider Monkey) +10.00%
03:14PM	Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview (GuruFocus.com)
11:33AM	Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates (Zacks)
10:35AM	Loading…
10:35AM	Q1 2024 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
May-09-24 05:39PM	Nektar: Q1 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2024 Financial Results (PR Newswire)
May-02-24 06:00PM	Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Apr-03-24 11:30AM	Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue? (Zacks) +9.47%
Mar-25-24 10:00AM	DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-22-24 02:00PM	Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference (PR Newswire)
Mar-06-24 12:33PM	Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata (Zacks)
Mar-05-24 10:07AM	Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat (Zacks)
09:13AM	Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:00AM	Loading…
09:00AM	Nektar Therapeutics Announces Initiation of Phase 2b Clinical Study Evaluating Rezpegaldesleukin in Patients with Severe to Very Severe Alopecia Areata (PR Newswire)
07:19AM	Q4 2023 Nektar Therapeutics Earnings Call (Thomson Reuters StreetEvents)
Mar-04-24 05:30PM	Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +15.38%
04:51PM	Nektar Therapeutics (NKTR) Reports Fiscal Year-End and Q4 2023 Results (GuruFocus.com)
04:42PM	Nektar: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results (PR Newswire)
08:30AM	Nektar Therapeutics Announces $30 Million Private Placement Financing with TCGX (PR Newswire)
Feb-27-24 06:00PM	Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference (PR Newswire) +11.94%
Feb-26-24 06:00PM	Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2023 on Monday, March 4, 2024, After Close of U.S.-Based Financial Markets (PR Newswire)
Feb-20-24 10:00AM	Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know (Zacks) -6.78%
Jan-03-24 06:00PM	Nektar Management To Present at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA (PR Newswire) -6.36%
Dec-11-23 06:00PM	Nektar and Collaborators Present Preclinical Data on NKTR-255 Combined with Obinutuzumab in Poster Presentation at the 65th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Dec-07-23 11:31AM	Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-09-23 08:39AM	Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript (Insider Monkey) -5.00%
Nov-08-23 11:47AM	Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss (Zacks) -8.76%
05:28PM	Loading…
Nov-07-23 05:28PM	Nektar: Q3 Earnings Snapshot (Associated Press Finance)
04:15PM	Nektar Therapeutics Reports Third Quarter 2023 Financial Results (PR Newswire)
Oct-31-23 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2023 on Tuesday, November 7, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-26-23 10:02AM	Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-23-23 10:08AM	12 Best Penny Stocks to Buy Under $1 (Insider Monkey) -7.11%
Oct-13-23 08:30AM	Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress (PR Newswire)
Oct-02-23 09:00AM	Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy (PR Newswire)
Sep-27-23 09:00AM	Nektar Therapeutics Announces New Clinical Study Collaboration with Cellular Biomedicine Group Inc. to Evaluate NKTR-255 in Combination with C-TIL051 in Advanced Non-Small Cell Lung Cancer (PR Newswire)
Sep-14-23 07:54AM	Nektar (NKTR) Up on Positive New Data From Eczema Study (Zacks)
Sep-13-23 09:00AM	Nektar Therapeutics Announces Promising New Data from Phase 1b Study of Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis (PR Newswire)
Sep-07-23 11:31AM	Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report? (Zacks)
Sep-06-23 06:00PM	Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th (PR Newswire)
Aug-17-23 07:02PM	RA Capital Management, L.P. Acquires Significant Stake in Nektar Therapeutics (GuruFocus.com) -6.26%
Aug-09-23 09:25AM	Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss (Zacks) -8.94%
Aug-08-23 05:30PM	Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:23PM	Nektar: Q2 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports Second Quarter 2023 Financial Results (PR Newswire)
11:08AM	Nektar Therapeutics sues Lilly for breach of contract around skin drug (American City Business Journals)
Aug-07-23 10:23AM	Nektar Therapeutics sues Eli Lilly over autoimmune disease treatment (Reuters) +91.51%
06:30AM	Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company (PR Newswire)
Aug-01-23 06:00PM	Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets (PR Newswire)
Jul-24-23 03:48AM	Zoetis (ZTS) Moves 6.9% Higher: Will This Strength Last? (Zacks) -5.69%
Jul-16-23 08:49AM	Nektar Therapeutics (NASDAQ:NKTR) is largely controlled by institutional shareholders who own 70% of the company (Simply Wall St.)
Jun-12-23 06:00PM	Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference (PR Newswire)
Jun-08-23 12:55PM	Investors Don't See Light At End Of Nektar Therapeutics' (NASDAQ:NKTR) Tunnel (Simply Wall St.)
11:31AM	Why Is Nektar (NKTR) Down 19.7% Since Last Earnings Report? (Zacks)
May-10-23 11:28AM	Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript (Insider Monkey)
09:16AM	Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat (Zacks)
May-09-23 06:45PM	Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:41PM	Nektar: Q1 Earnings Snapshot (AP Finance)
04:15PM	Nektar Therapeutics Reports First Quarter 2023 Financial Results (PR Newswire)
May-08-23 09:29AM	Biotech Stocks' Q1 Earnings on May 9: NVAX, EBS & More (Zacks) -5.94%
May-04-23 10:00AM	Earnings Preview: Marinus Pharmaceuticals (MRNS) Q1 Earnings Expected to Decline (Zacks)
May-02-23 10:01AM	Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-27-23 08:30AM	Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development (PR Newswire)
Apr-19-23 08:38AM	Zacks.com featured highlights include Disney, Casey's General Stores, OpGen, Accelerate Diagnostics and Nektar Therapeutics (Zacks)
Apr-17-23 05:00PM	Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan (PR Newswire) +6.26%
Apr-16-23 06:30AM	7 Sorry Pharma Stocks to Sell in April Before Its Too Late (InvestorPlace)
Apr-13-23 10:59AM	Here's Why You May Add Nektar (NKTR) Stock to Your Portfolio (Zacks) +10.16%
Apr-11-23 08:57AM	Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, KalVista Pharmaceuticals, Larimar Therapeutics, Nektar Therapeutics and Jounce Therapeutics (Zacks) +10.53%
Apr-10-23 10:07AM	5 Stocks to Buy as the Drug Industry Rebounds in 2023 (Zacks) +6.57%
Apr-02-23 08:27AM	We Think Nektar Therapeutics (NASDAQ:NKTR) Needs To Drive Business Growth Carefully (Simply Wall St.)
Mar-30-23 11:30AM	Why Is Nektar (NKTR) Down 51.9% Since Last Earnings Report? (Zacks) -12.42%
Mar-29-23 05:44PM	Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600 (PR Newswire)
Mar-24-23 12:00PM	Nektar (NKTR) Upgraded to Buy: Here's Why (Zacks)
Mar-22-23 09:35AM	Down -69.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Nektar (NKTR) (Zacks) -9.73%
Mar-14-23 03:43AM	Sage Therapeutics, Inc. (SAGE) Soars 9.6%: Is Further Upside Left in the Stock? (Zacks)
Feb-28-23 05:15PM	Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results (PR Newswire)
Feb-24-23 10:23AM	Why Nektar Therapeutics Stock Is Plunging Today (Benzinga) -49.66%
07:29AM	Boeing stock slips after deliveries of 787s halted; Beyond Meat shares rally after plant-food makers results (MarketWatch)
Feb-23-23 06:20PM	UPDATE 1-Nektar Therapeutics' autoimmune disease drug fails mid-stage study (Reuters)
05:24PM	Nektar stock drops more than 30% after study involving lupus treatment will not go forward (MarketWatch)
04:30PM	Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus (PR Newswire)
Jan-09-23 09:04AM	Concert (CNCE) Moves 19.3% Higher: Will This Strength Last? (Zacks)
Jan-04-23 09:00AM	Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA (PR Newswire) +6.85%
Dec-12-22 10:05AM	Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting (PR Newswire)
Dec-05-22 08:00AM	Nektar Therapeutics to Host Investor & Analyst Event on December 12th (PR Newswire)
Nov-10-22 09:05AM	Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting (PR Newswire) +8.66%
07:58AM	Nektar Therapeutics Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-09-22 09:00AM	Nektar and Collaborators Announce Publication in Blood Advances of Preclinical Data Demonstrating NKTR-255, a Novel Polymer-conjugated Human IL-15, Improves Efficacy of CD19-targeted CAR-T Cell Immunotherapy (PR Newswire) -5.54%
Nov-04-22 12:35PM	Nektar's (NKTR) Q3 Earnings and Revenues Beat Estimates (Zacks) +5.90%
Nov-03-22 06:35PM	Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-28-22 10:00AM	ImmunoGen (IMGN) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-22 10:02AM	Nektar Therapeutics (NKTR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-25-22 06:00PM	Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets (PR Newswire)
Oct-24-22 07:55AM	Here's Why We're Watching Nektar Therapeutics' (NASDAQ:NKTR) Cash Burn Situation (Simply Wall St.)
Oct-11-22 05:13PM	Why a S.F. biotech and its potential merger partner pulled the plug on talks (American City Business Journals)
Oct-07-22 03:42PM	Longtime S.F. biotech in talks with London company on 'combination' (American City Business Journals)
11:21AM	PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics (Benzinga)
Sep-07-22 01:15AM	Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress (PR Newswire)

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes therapies for oncology, immunology and virology. The firm focuses on using new chemistry approaches to make medicines to treat cancer and autoimmune diseases. The company was founded in 1990 and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
CHESS ROBERT	Director	Jun 14 '24	Sale	1.20	19,500	23,400	255,273	Jun 14 06:02 PM
ROBIN HOWARD W	President & CEO	May 17 '24	Sale	1.75	16,650	29,138	863,239	May 20 09:14 PM
Zalevsky Jonathan	Chief R&D Officer	May 17 '24	Sale	1.75	7,355	12,871	257,670	May 20 09:13 PM
Wilson Mark Andrew	Chief Legal Officer	May 17 '24	Sale	1.75	6,260	10,955	230,414	May 20 09:12 PM
Deep Track Capital, LP	10% Owner	May 10 '24	Sale	1.78	56,000	99,630	18,344,000	May 13 04:36 PM
ROBIN HOWARD W	President & CEO	Feb 20 '24	Sale	0.68	20,033	13,622	879,889	Feb 22 08:16 PM
Zalevsky Jonathan	Chief R&D Officer	Feb 20 '24	Sale	0.68	9,014	6,130	265,025	Feb 22 08:19 PM
Wilson Mark Andrew	Chief Legal Officer	Feb 20 '24	Sale	0.68	7,606	5,172	236,674	Feb 22 08:17 PM
ROBIN HOWARD W	President & CEO	Nov 17 '23	Sale	0.49	19,877	9,740	899,922	Nov 20 08:58 PM
Zalevsky Jonathan	Chief R&D Officer	Nov 17 '23	Sale	0.49	9,646	4,727	274,039	Nov 20 09:02 PM
Wilson Mark Andrew	Chief Legal Officer	Nov 17 '23	Sale	0.49	7,179	3,518	243,780	Nov 20 09:00 PM
Curet Myriam	Director	Sep 18 '23	Sale	0.69	4,359	3,008	27,418	Sep 20 08:09 PM
Ajer Jeffrey Robert	Director	Sep 18 '23	Sale	0.69	4,359	3,008	34,153	Sep 20 08:06 PM
ROBIN HOWARD W	President & CEO	Aug 16 '23	Sale	0.78	19,998	15,598	919,799	Aug 17 08:06 PM
Zalevsky Jonathan	Chief R&D Officer	Aug 16 '23	Sale	0.78	9,703	7,568	283,685	Aug 17 08:08 PM
Wilson Mark Andrew	Chief Legal Officer	Aug 16 '23	Sale	0.78	7,221	5,632	250,959	Aug 17 08:07 PM

Open in Screener

RZLT

Rezolute Inc

Jun 17 • 01:49PM ET

3.97

Dollar change +0.02
Percentage change 0.63	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VXF IWC DFAT DFAS DFAC AVSC

Index	-	P/E	-	EPS (ttm)	-1.14	Insider Own	22.86%	Shs Outstand	36.83M	Perf Week	-26.93%
Market Cap	159.56M	Forward P/E	-	EPS next Y	-0.93	Insider Trans	86.39%	Shs Float	30.91M	Perf Month	55.27%
Income	-58.21M	PEG	-	EPS next Q	-0.32	Inst Own	60.94%	Short Float	2.64%	Perf Quarter	122.07%
Sales	0.00M	P/S	-	EPS this Y	-17.70%	Inst Trans	-0.33%	Short Ratio	1.26	Perf Half Y	352.79%
Book/sh	1.77	P/B	2.25	EPS next Y	22.19%	ROA	-52.46%	Short Interest	0.81M	Perf Year	93.90%
Cash/sh	1.99	P/C	1.99	EPS next 5Y	-	ROE	-58.75%	52W Range	0.72 - 6.10	Perf YTD	300.50%
Dividend Est.	-	P/FCF	-	EPS past 5Y	48.08%	ROI	-80.09%	52W High	-34.83%	Beta	1.20
Dividend TTM	-	Quick Ratio	11.82	Sales past 5Y	0.00%	Gross Margin	-	52W Low	452.08%	ATR (14)	0.54
Dividend Ex-Date	-	Current Ratio	11.82	EPS Y/Y TTM	-6.90%	Oper. Margin	0.00%	RSI (14)	47.52	Volatility	9.91% 14.25%
Employees	51	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	10.57
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-10.10%	Payout	-	Rel Volume	0.92	Prev Close	3.95
Sales Surprise	-	EPS Surprise	-12.81%	Sales Q/Q	-	Earnings	May 15 AMC	Avg Volume	647.91K	Price	3.97
SMA20	-6.59%	SMA50	16.09%	SMA200	122.93%	Trades		Volume	405,738	Change	0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-24	Initiated	Craig Hallum	Buy	$14
Apr-09-24	Initiated	Maxim Group	Buy	$8
Aug-02-22	Resumed	Canaccord Genuity	Buy	$17
Jun-15-22	Initiated	Cantor Fitzgerald	Overweight	$9
Sep-08-21	Initiated	ROTH Capital	Buy	$21
May-27-21	Initiated	Oppenheimer	Outperform	$25
May-25-21	Initiated	H.C. Wainwright	Buy	$21

Jun-14-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -23.45%
Jun-13-24 11:30PM	Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants (GlobeNewswire) -5.84%
04:01PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
May-30-24 08:00AM	Rezolute to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-24 07:23AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -6.33%
06:27AM	Loading…
06:27AM	Rezolute's oral Eylea rival hits phase 2 goal, sending stock up and sparking partnership talk (FierceBiotech.com)
May-21-24 04:05PM	Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME) (GlobeNewswire) +6.76%
May-15-24 10:54PM	RZLT Stock Earnings: Rezolute Misses EPS for Q3 2024 (InvestorPlace)
04:05PM	Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-23-24 08:00AM	Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting (GlobeNewswire) -19.21%
Mar-20-24 02:33PM	Hedge Fund and Insider Trading News: Ken Griffin, Nelson Peltz, Palliser Capital, Elliott Management, Three Arrows Capital, Rezolute, Inc. (RZLT), Tesla Inc (TSLA), and More (Insider Monkey)
Mar-06-24 07:30AM	Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH) (GlobeNewswire)
Feb-13-24 04:05PM	Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update (GlobeNewswire)
Jan-24-24 08:00AM	Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer (GlobeNewswire) +6.37%
Jan-23-24 08:00AM	Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism (GlobeNewswire)
08:00AM	Loading…
Dec-14-23 08:00AM	Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism (GlobeNewswire)
Dec-13-23 08:00AM	Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema ( DME ) (GlobeNewswire) +8.37%
Nov-24-23 11:14AM	Stonegate Healthcare Partners Announces Black Friday Biotech Special Report For an 'XBI-MAS' (Newsfile)
Nov-17-23 08:00AM	Rezolute to Participate in BTIG's 3rd Annual Ophthalmology Day (GlobeNewswire)
Nov-13-23 04:05PM	Rezolute Reports First Quarter Fiscal 2024 Results (GlobeNewswire) +12.22%
Oct-17-23 08:00AM	Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +6.52%
Oct-11-23 08:00AM	Rezolute Announces Further Evidence of RZ358's Efficacy in Tumor-Mediated Hyperinsulinism (GlobeNewswire) -6.00%
Sep-14-23 04:05PM	Rezolute Reports Full Year Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Sep-06-23 07:00AM	Rezolute to Participate in Upcoming Investor Conferences in September (GlobeNewswire)
Jun-27-23 04:05PM	Rezolute to Initiate a Pivotal Phase 3 Study of RZ358 in Participants 3 Months of Age and Older with Congenital Hyperinsulinism (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile) -7.51%
May-11-23 04:05PM	Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Mar-23-23 04:50PM	Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema (GlobeNewswire) -5.34%
Mar-08-23 07:00AM	Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert (GlobeNewswire) +7.44%
Feb-10-23 04:05PM	Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
07:00AM	Loading…
Dec-15-22 07:00AM	Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema (GlobeNewswire)
Nov-09-22 04:05PM	Rezolute Reports First Quarter Fiscal 2023 Results and Highlights Company Progress (GlobeNewswire)
Nov-01-22 07:00AM	Rezolute to Present at the Jefferies London Healthcare Conference (GlobeNewswire)
Oct-20-22 07:00AM	Rezolute Announces Presentation at The Retina Society 55th Annual Scientific Meeting (GlobeNewswire)
Sep-15-22 04:05PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2022 Results and Highlights Company Progress (GlobeNewswire)
Sep-07-22 07:00AM	Rezolute Announces Presentation at the 60th Annual ESPE Meeting (GlobeNewswire)
Aug-15-22 08:36AM	Here's What Rezolute, Inc.'s (NASDAQ:RZLT) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Jun-01-22 07:00AM	Rezolute Announces Promotion of Brian Roberts, M.D. to Chief Medical Officer (GlobeNewswire)
May-12-22 04:05PM	Rezolute Reports Third Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire)
May-04-22 04:01PM	Rezolute to Host Corporate Update Call on May 4, 2022 (GlobeNewswire)
09:33AM	Rezolute, Inc. Announces Closing of Registered Direct Offering (GlobeNewswire)
May-01-22 11:25PM	Rezolute, Inc. Announces Aggregate $130 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market (GlobeNewswire)
02:00PM	Rezolute Announces Positive Data from its Phase 2b (RIZE) Study of RZ358 in Patients with Congenital Hyperinsulinism (GlobeNewswire)
Apr-26-22 04:05PM	RZ358 Phase 2b (RIZE Study) Topline Data to be Unveiled at Pediatric Endocrine Society Annual Meeting on May 1, 2022 (GlobeNewswire) -7.74%
Mar-29-22 07:00AM	Rezolute Joins the Rare Disease Company Coalition (GlobeNewswire) -8.72%
Mar-23-22 07:00AM	Rezolute Announces Positive Results from the Phase 2b RIZE Study of RZ358 in Congenital Hyperinsulinism (GlobeNewswire) +7.34%
Feb-22-22 07:00AM	Rezolute Announces Positive Study Results for RZ402, an oral PKI being developed for DME (GlobeNewswire) -6.18%
Feb-09-22 04:05PM	Rezolute Reports Second Quarter Fiscal 2022 Financial Results and Highlights Company Progress (GlobeNewswire)
Nov-12-21 04:05PM	Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-19-21 12:14PM	Do Institutions Own Rezolute, Inc. (NASDAQ:RZLT) Shares? (Simply Wall St.)
Oct-13-21 08:10AM	Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering (GlobeNewswire) -14.19%
Oct-12-21 04:05PM	Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering (GlobeNewswire)
Sep-22-21 04:05PM	Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021 (GlobeNewswire)
Sep-15-21 04:56PM	Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Sep-09-21 04:05PM	Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism (GlobeNewswire)
Sep-07-21 04:05PM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire) +5.41%
Aug-10-21 07:00AM	Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolutes Oral PKI for Treatment of DME (GlobeNewswire) +6.37%
Aug-03-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire)
Jun-28-21 07:00AM	Rezolute Added to Russell Microcap® Index (GlobeNewswire)
Jun-24-21 09:01PM	Oppenheimer Bets on These 2 Stocks; Sees at Least 80% Upside Ahead (TipRanks)
Jun-03-21 05:35AM	Will Rezolute (NASDAQ:RZLT) Spend Its Cash Wisely? (Simply Wall St.)
May-31-21 10:17AM	3 Strong Buy Stocks with 100% Upside Potential (TipRanks)
May-27-21 07:00AM	Rezolute to Participate in Upcoming Virtual Healthcare Conferences (GlobeNewswire) +40.31%
May-20-21 07:00AM	Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs (GlobeNewswire)
May-18-21 07:00AM	Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board (GlobeNewswire)
May-17-21 04:05PM	Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
07:00AM	Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit (GlobeNewswire)
May-04-21 08:00AM	Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema (GlobeNewswire)
Apr-19-21 08:00AM	Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners (GlobeNewswire)
Mar-22-21 08:00AM	Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021 (GlobeNewswire)
Mar-08-21 08:00AM	Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts (GlobeNewswire) +24.96%
Mar-02-21 05:16PM	Rezolute to Participate in Upcoming Investor Conferences in March (GlobeNewswire) -5.34%
Feb-10-21 04:05PM	Rezolute Reports Second Quarter Fiscal 2021 Financial Results (GlobeNewswire) -9.07%
Jan-12-21 08:30AM	Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema (GlobeNewswire) +6.84%
Jan-11-21 07:56AM	What Is The Ownership Structure Like For Rezolute, Inc. (NASDAQ:RZLT)? (Simply Wall St.) -6.15%
Dec-28-20 04:05PM	Rezolute Announces Change of Transfer Agent (GlobeNewswire)
Dec-03-20 08:00AM	FDA Clears Rezolutes IND Application for RZ402 (GlobeNewswire) +7.64%
Nov-19-20 08:00AM	Rezolute to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference (GlobeNewswire)
Nov-05-20 08:00AM	Rezolute Announces Uplisting to the Nasdaq Capital Market (GlobeNewswire) +11.11%
Oct-09-20 08:30AM	Rezolute Announces $41 Million Private Placement with Leading Investment Firms and Prepares to Imminently Up-list to Nasdaq (GlobeNewswire) +8.75%
Sep-10-20 08:00AM	Rezolute, Inc. Welcomes Pharmaceutical Industry Leader Philippe Fauchet to its Board of Directors (GlobeNewswire)
Jul-27-20 08:00AM	Rezolute, Inc. Provides Updates in the Context of the COVID-19 Pandemic: Announces Resumption and US-Expansion of its Phase 2b Study in Congenital Hyperinsulinism (GlobeNewswire)
Jun-15-20 08:30AM	Rezolute Announces Publication of RZ402 Data in Diabetic Macular Edema (DME) in Investigative Ophthalmology & Visual Science (GlobeNewswire) -10.58%
May-28-20 08:30AM	Rezolute to Present Clinical Data for RZ358, Lead Candidate in Phase 2b Trial in Congenital Hyperinsulinism at Virtual Pediatric Endocrine Society 2020 Annual Meeting (GlobeNewswire)

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperinsulinism, AB101-Phase 1, a once-weekly injectable basal insulin, and RZ402, which targets diabetic macular edema. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada on July 26, 2010 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Evans Daron	CFO	Jun 14 '24	Buy	4.04	40,000	161,568	40,000	Jun 14 12:06 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 14 '24	Buy	3.91	4,300	16,828	54,352	Jun 14 12:51 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 14 '24	Buy	3.91	3,300	12,916	13,000	Jun 14 12:51 PM
Evans Daron	CFO	May 29 '24	Buy	3.50	451	1,578	121,351	May 31 04:05 PM
Evans Daron	CFO	May 24 '24	Buy	3.23	2,942	9,503	13,000	May 28 02:48 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	May 23 '24	Buy	2.69	7,500	20,138	50,052	May 28 02:56 PM
Evans Daron	CFO	May 23 '24	Buy	2.85	58	165	10,058	May 28 02:48 PM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 28 '24	Buy	2.55	500	1,275	1,076	Mar 29 11:08 AM
Evans Daron	CFO	Mar 15 '24	Buy	1.69	20,000	33,830	20,000	Mar 19 09:17 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 14 '24	Buy	1.88	10,000	18,800	10,000	Mar 18 11:20 AM
Evans Daron	CFO	Mar 08 '24	Buy	1.93	50,000	96,345	120,900	Mar 08 12:37 PM
Kim Young-Jin	Director	Mar 07 '24	Buy	1.91	36,503	69,859	115,450	Mar 14 10:35 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Mar 07 '24	Buy	1.85	500	925	500	Mar 11 10:35 AM
Elam Nevan C	CEO	Feb 26 '24	Buy	1.68	5,000	8,400	7,817	Feb 28 11:40 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 26 '24	Buy	1.70	2,000	3,400	42,552	Feb 27 08:47 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 23 '24	Buy	1.69	6,000	10,140	40,552	Feb 27 08:47 AM
Evans Daron	CFO	Feb 16 '24	Buy	1.30	41,900	54,411	70,900	Feb 20 07:01 AM
Evans Daron	CFO	Feb 16 '24	Buy	1.37	9,000	12,330	4,500	Feb 20 07:01 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Feb 16 '24	Buy	1.31	7,000	9,142	34,552	Feb 21 11:55 AM
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jul 03 '23	Buy	1.90	5,000	9,500	27,552	Jul 06 11:18 AM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

NKTR

Nektar Therapeutics

RZLT

Rezolute Inc

Upgrade your FINVIZ experience